Emerging evidence has demonstrated the critical roles for both androgen and Wnt pathways in prostate tumorigenesis. A recent integrative genomic analysis of human prostate cancers (PCas) has revealed a unique enrichment of androgen and Wnt signaling in early-onset PCas, implying their clinical significance in the disease. Additionally, interaction between the androgen receptor (AR) and β-catenin has long been detected in PCa cells. However, the consequence of this interaction in prostate tumorigenesis is still unknown. Because mutations in adenomatous polyposis coli, β-catenin and other components of the destruction complex are generally rare in PCas, other mechanisms of aberrant Wnt signaling activation have been speculated. To address these critical questions, we developed Ctnnb1 L(ex3)/+ /R26hAR L/+ :PB-Cre4 mice, in which transgenic AR and stabilized β-catenin are co-expressed in prostatic epithelial cells. We observed accelerated tumor development, aggressive tumor invasion and a decreased survival rate in Ctnnb1 L(ex3)/+ /R26hAR L/+ :PB-Cre4 compound mice compared with age-matched Ctnnb1 L(ex3)/+ :PB-Cre4 littermate controls, which only have stabilized β-catenin expression in the prostate. Castration of the above transgenic mice resulted in significant tumor regression, implying an essential role of androgen signaling in tumor growth and maintenance. Implantation of the prostatic epithelial cells isolated from the transgenic mice regenerated prostate intraepithelial neoplasias and prostatic adenocarcinoma lesions. Microarray analyses of transcriptional profiles showed more robust enrichment of known tumor-and metastasis-promoting genes: Spp1, Egr1, c-Myc, Sp5, and Sp6 genes, in samples isolated from Ctnnb1 L(ex3)/+ /R26hAR L/+ :PB-Cre4 compound mice than those from Ctnnb1 L(ex3)/+ :PB-Cre4 and R26hAR L/+ :PB-Cre4 littermate controls. Together, these data demonstrate a confounding role of androgen signaling in β-catenin-initiated oncogenic transformation in prostate tumorigenesis.
INTRODUCTION
Androgen signaling, mediated through the androgen receptor (AR) and its ligands, testosterone and 5α-dihydrotestosterone, is essential for prostate tumorigenesis. [1] [2] [3] Androgen-deprivation therapy inhibits androgen signaling-mediated cell growth and survival and thus has been widely used to treat prostate cancer (PCa). 4 The AR is expressed in most PCa samples before and after the therapy. 5 In fact, AR gene amplification appears in one-third of PCa samples after androgen-deprivation therapy. 6 Additionally, global gene-expression profiling shows that the AR is one of the several genes to be consistently upregulated in castrationresistant prostate cancer, 7, 8 underscoring the significance of androgen signaling in prostate tumorigenesis.
Likewise, Wnt signaling pathways have a significant role in prostate tumorigenesis. 9 Abnormal expression of Wnt ligands, receptors and effectors has been identified in PCa cells and cells of the surrounding microenvironments, suggesting paracrineregulatory mechanisms in prostate tumorigenesis. 10, 11 In the canonical signaling pathway, secreted Wnt ligands bind to Frizzled proteins and regulate the stability of β-catenin, a key component of Wnt signaling. 12 In the absence of a Wnt signal, β-catenin is constitutively downregulated by a multicomponent destruction complex containing glycogen synthase kinase 3β, axin and adenomatous polyposis coli (APC), promoting phosphorylation on serine and threonine residues in the N-terminal region of β-catenin following 'priming' phosphorylation of Ser45 by Casein Kinase I and thereby targeting it for degradation via the ubiquitin proteasome pathway. [13] [14] [15] [16] Increase in nuclear β-catenin has been shown to promote PCa cell proliferation. 17 In mice, expression of stabilized β-catenin in the prostate induces the development of squamous metaplasia, prostate intraepithelial neoplasias (PIN) 18, 19 and prostate adenocarcinoma. 20 Conditional deletion of APC in the mouse prostate elevates nuclear β-catenin and results in prostatic adenocarcinoma formation. 21 Intriguingly, mutations in APC, β-catenin and other components of the β-catenin destruction complex are rare in human PCa, 22, 23 suggesting alternative mechanisms of β-catenin dysregulation in prostate tumorigenesis. One of such alternative mechanisms is the hypermethylation of the APC promoter region, which ultimately results in aberrant activation of β-catenin/Wnt signaling pathway. In fact, APC promoter hypermethelation in PCa has been correlated with poor clinical prognosis 24 and recently has been proposed as one of the prognostic PCa markers. 25 Despite the elusiveness of aberrant Wnt activation, an interaction between the AR and β-catenin proteins has been identified in PCa cells. [26] [27] [28] A recent integrative genomic study revealed a significant enrichment of the androgen and Wnt signaling pathways in the early-onset PCa samples but not in the elderlyonset PCa samples, 29 which further implicates a clinical importance of both androgen and Wnt signaling in prostate tumorigenesis. However, the biological significance of this interaction in the pathogenesis of PCa remains unknown. To address this critical question and recapitulate the AR and β-catenin interaction in vivo, we developed Ctnnb1 L(ex3)/+ /R26hAR L/+ :PB-Cre4 mice, in which transgenic AR and stabilized β-catenin are co-expressed in prostatic epithelial cells. We observed accelerated tumor development, aggressive tumor invasion and a decreased survival rate in these compound mice versus control littermates. Castration of these mice resulted in significant tumor regression. Moreover, implantation of prostatic epithelial cells isolated from the compound mice regenerated much severe PIN and prostatic adenocarcinoma lesions in tissue recombination assays. Furthermore, we detected increased expression of known protumorigenic and pro-metastatic genes Spp1, Egr1, c-Myc and Sp6 in the prostates of the compound mice. These data demonstrate a confounding role of androgen signaling in β-catenin-mediated oncogenic transformation in prostate tumorigenesis.
RESULTS
Activation of transgenic AR expression accelerates oncogenic transformation in the mouse prostate Although an interaction between the androgen and Wnt signaling pathways has been identified in PCa cells, the significance of this interaction in prostate tumorigenesis remains unclear. Specifically, we still do not know whether these two pathways can synergistically promote PCa initiation and progression. To address this question, we developed Ctnnb1 L(ex3)/+ /R26hAR L/+ :PB-Cre4 mice, in which expression of human AR transgene and stabilized β-catenin were activated through the probasin promoter-driven Cre expression in the mouse prostate ( Figure 1a ). Using genomic PCR and western blotting analyses, we confirmed LoxP/Cre-mediated recombination events (Figure 1b) , resulting in human AR and stabilized β-catenin protein expression in mouse prostate tissues
:PB-Cre4 mice were born at the expected Mendelian ratios and appeared normal with no obvious differences from their wild-type littermates at birth. We systematically examined male mice at 3, 4, 5, 6 and 8 weeks of age (Supplementary Figure S1) . Consistent with previous reports, 30, 31 we did not observe any obvious abnormalities in 2-to 12-month-old R26hAR L/+ :PB-Cre4 mice (data not shown). Adhering to recommendations of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee, 32 we first identified prostatic hyperplasia and mPIN1 in 4-week-old Ctnnb1 L(ex3)/+ :PB-Cre4 mice (Figure 1d1 ; Supplementary Figures S1B1 and B2). These lesions originated predominantly in the dorsal/lateral prostate and ventral prostate lobes. Over time, it appears that these low-grade mPIN lesions progressed toward high-grade mPIN lesions (mPIN3 and mPIN4) (Supplementary Figures S1D1, D2, E1 and E2). Notably, Ctnnb1 L(ex3)/+ /R26hAR L/+ :PB-Cre4 compound mice, with transgenic AR and stabilized β-catenin co-expression in the prostate, developed PIN lesions earlier than Ctnnb1 L(ex3)/+ :PB-Cre4 mice. We observed mPIN1 and mPIN2 lesions at 3 weeks of age (Supplementary Figure S1A4) , and mPIN3 and mPIN4 lesions at 5 weeks in Ctnnb1 L(ex3)/+ /R26hAR L/+ :PB-Cre4 mice (Supplementary Figures S1C3 and C4) . Additionally, squamous metaplasia appeared in both Ctnnb1 L(ex3)/+ :PB-Cre4 and Ctnnb1 L(ex3)/+ / R26hAR L/+ :PB-Cre4 mice (Supplementary Figure S1C3) . Expression of stabilized β-catenin was confirmed in prostatic epithelial cells in both Transgenic AR and stabilized β-catenin co-expression synergistically enhances cell proliferation In this study, we examined the effect of co-expressing stabilized β-catenin and transgenic AR in promoting cell proliferation in the transgenic mice using Ki67 immunohistochemistry. A significant increase of Ki67-positive cells was observed in the samples of
:PB-Cre4 mice (Figures 3c1-e2 ). We quantified Ki67-positive cells per 1000 epithelial cells from five fields on three different slides that were prepared independently from three mice of each genotype. As shown in Figure 3f , the epithelial proliferative index was the highest in the tumor lesions of Ctnnb1 L(ex3)/+ /R26hAR L/+ :PB-Cre4 mice, suggesting a synergistic role of transgenic AR and stabilized β-catenin co-expression in promoting cell proliferation in the mouse prostate.
Transgenic AR and stabilized β-catenin co-expression induces oncogenic transformation predominantly in prostatic luminal cells To further define the cellular properties of prostatic pathologies developed in Ctnnb1 L(ex3)/+ :PB-Cre4, and Ctnnb1 L(ex3)/+ :R26hAR L/+ : PB-Cre4 :mice, we comprehensively analyzed different cellular markers in both higher-grade PIN and adenocarcinoma lesions ( Figure 4 ). Effect of abnormal activation of AR and β-catenin in inducing prostatic oncogenesis in tissue recombinants In this study, we assessed the oncogenic potential of transgenic AR and stabilized β-catenin-expressing cells to regenerate cancerous cells using a tissue recombination system. In the double-fluorescent mT/mG Cre reporter mouse strain, the expression of membrane targeted tandem dimer Tomato (mT) or Figure 2 . The synergistic effect of AR and Wnt signaling in mouse prostate tumor progression. Corresponding gross photographs (a1-b2), subgross photomicrographs (c1-d2), and photomicrographs (e-h) of prostrate gland with seminal vesicles and urinary bladder from 3-to 4-month-old Ctnnb1 membrane-targeted green fluorescent protein (mG) is controlled by Cre-mediated recombination, where Cre-expressing cells contain mG and can be sorted from mT cells. 33 We first generated and analyzed specific mG protein expression in prostatic luminal epithelial cells controlled by PB-Cre-mediated recombination, allowing for the selection of recombined cells, in mT/mG:PB-Cre mice (Supplementary Figure S3) . We then produced both mT/mG/ Ctnnb1 L(ex3)/+ :PB-Cre4 and mT/mG/ Ctnnb1 L(ex3)/+ /R26hAR L/+ :PB-Cre4 mice to specifically label stabilized β-catenin only or stabilized β-catenin/transgenic AR-positive cells (Figures 5a and b) . Singlecell suspensions prepared from prostate tumors of 3-month-old mT/mG/Ctnnb1 L(ex3)/+ :PB-Cre4 or mT/mG/Ctnnb1 L(ex3)/+ /R26hAR L/+ : PB-Cre4 mice mixed with embryonic urogenital sinus mesenchymal (UGSM) cells were transplanted under the renal capsule of NOD/SCID mice and analyzed after 12 weeks. Grafts composed solely of UGSM cells appeared small and fibrous and mainly contained stromal-like cells. However, large translucent grafts were observed in grafts containing both UGSM and prostatic epithelial cells. Histological analysis of these grafts showed tubular epithelial structures with prostatic-like ducts filled with fluid (Figures 5c and d) . We observed typical high-grade PIN or multifocal intracystic adenocarcinoma lesions in tissue recombinant grafts prepared with prostatic epithelial cells isolated from mT/mG/Ctnnb1 Co-expression of transgenic AR and/or stabilized β-catenin, as well as mG protein, was detected in atypical and tumor cells of all graft samples (Figures 5e and p) . These data further demonstrate the oncogenic capacity of transgenic AR and stabilized β-catenin in regenerating cancerous glandular structures in the mouse prostate.
Androgen signaling is a confounding factor for β-catenin-initiated oncogenic transformation Early-onset and rapidly progressing tumor phenotype in Ctnnb1
:PB-Cre4 compound mice suggests a promotional role of androgen signaling in β-catenin-mediated oncogenic transformation. Thus we evaluated the effect of castration on tumor development, maintenance and progression in the transgenic mice. Given the fact that PINs developed as early as 3 weeks in Ctnnb1 L(ex3)/+ /R26hAR L/+ :PB-Cre4 mice, we castrated R26hAR :PB-Cre4 mice at 2 weeks of age and analyzed them at 16 weeks of age to determine the effect of androgens in initiating oncogenic transformation in the prostate (Figure 6a ). We observed underdeveloped prostate lobes in all three different genotypes of mice, featuring markedly atrophic glandular/ductal profiles in combination with a relatively prominent concentric peri-glandular/-ductular fibromuscular stroma (Figures 6b and d') . Importantly, there were no proliferative, dysplasic and mPIN pathological changes in Ctnnb1 L(ex3)/+ :PB-Cre4 nor Ctnnb1 L(ex3)/+ /R26hAR L/+ :PBCre4 mice, contrasting to those in age-and genotype-matched intact mice (Figure 1) , which implicates an essential role of androgens in initiating oncogenic transformation of the prostate. To assess androgens in promoting tumor growth and progression, we castrated Ctnnb1 L(ex3)/+ :PB-Cre4 and Ctnnb1 L(ex3)/+ /R26hAR L/+ : PB-Cre4 mice at 6 weeks, after high-grade PINs have already developed, and then analyzed them at 16 weeks (Figure 6a ). Prostate lobes were grossly smaller than the age-matched intact mice, and histological analysis showed some residual mPIN-like lesions as well as remnants of sloughed, intraluminal keratin. However, the epithelial cells lining these mPIN-like lesions consisted of 1-2 cell layers of uniform cuboidal cells with minimal nuclear atypia (Figures 6e and h') (Figure 6a ). Although residual lower-grade mPIN lesions still remained, no tumor masses were observed in all the examined samples isolated from Ctnnb1 L(ex3)/+ /R26hAR L/+ :PB-Cre4 mice castrated at 16 weeks (Figures 6i and l') . We also detected Figures S5D-G') . These experiments further demonstrate a reliance on androgens in β-catenin-mediated oncogenic transformation in the mouse prostate.
Identification of downstream targets that promote prostate tumor initiation and progression Next we performed microarray analyses to investigate the molecular basis by which transgenic AR and stabilized β-catenin expression may promote prostate tumorigenesis in these transgenic mice. We carefully isolated prostatic tumor tissues from 4-month-old Ctnnb1 (Figures 7b and c) , implying the need for both transgenic AR and stabilized β-catenin expression in regulating transcription of these genes. Intriguingly, previous studies have implicated the promotional roles of these gene products in PCa initiation and progression. [34] [35] [36] Using immunohistochemistry, we demonstrated an increased expression of Spp1 and Egr-1 proteins in the prostates of Ctnnb1 L(ex3)/+ /R26hAR L/+ :PB-Cre4 mice (Figure 7d ). Expression levels of Lef1, Axin2 and Cd44, which have been documented as β-catenin downstream targets, were higher in the samples isolated from Ctnnb1 L(ex3)/+ :PB-Cre4 mice than those from Ctnnb1 L(ex3)/+ /R26hAR L/+ :PB-Cre4 mice (Figure 7c) . Additionally, to further explore the possible molecular basis for stabilized β-catenin and transgenic AR in regulating gene expression, we performed chromatin immunoprecipitation (ChIP) assay with prostatic cells isolated from 3-month-old Ctnnb1 L(ex3)/+ :PB-Cre4 and Ctnnb1 L(ex3)/+ /R26hAR L/+ :PB-Cre4 mice. We analyzed the mouse c-Myc locus, one of the upregulated genes in prostate tissues isolated from Ctnnb1 L(ex3)/+ /R26hAR L/+ :PB-Cre4 mice with the immunoprecipitated genomic DNA by qPCR using specific primers spanning the mouse c-Myc locus (Figure 7e) . 37 We observed the recruitment of both AR and β-catenin at β-catenin/TCF4-binding regions on the mouse c-Myc locus (Figure 7f) . Interestingly, the enrichments of β-catenin and AR at β-catenin/TCF4-binding regions were higher in the samples isolated from Ctnnb1 L(ex3)/+ / R26hAR L/+ :PB-Cre4 mice than ones from Ctnnb1 L(ex3)/+ :PB-Cre4 mice. Overall, the data indicate that co-activation of transgenic AR and β-catenin expression regulates the transcription of a unique subset of genes, which may contribute to prostate tumor initiation and progression.
DISCUSSION
It has been over a decade since the interaction between AR and β-catenin has been demonstrated in PCa cells. [26] [27] [28] 38 However, the biological consequences of this interaction in prostate tumorigenesis remain unclear. In this study, we directly addressed this long-term unclear question using a series of newly developed mouse models. We observed accelerated invasive tumor development and a shortened survival in Ctnnb1 L(ex3)/+ /R26hAR L/+ : PB-Cre4 mice, in which the expression of both transgenic AR and stabilized β-catenin proteins is concurrent in prostate epithelial cells. In contrast, Ctnnb1 L(ex3)/+ :PB-Cre4 mice, which only have stabilized β-catenin expression in the prostate, displayed a milder tumor phenotype. Because endogenous AR expression exists in prostatic luminal cells of Ctnnb1 L(ex3)/+ :PB-Cre4 mice and castration prior to puberty did not result in tumor development, our observation implies an essential role for androgen signaling in enhancing β-catenin-mediated prostate tumor initiation. Importantly, a recent study has shown an enrichment of AR and Wnt signaling pathways in early-onset PCa, but not in elderly-onset PCa, 29 highlighting a clinical significance for this study. As mutations in APC, β-catenin and other components of the β-catenin destruction complex have rarely been detected in PCa cells, results from this current study suggest a possible mechanism underlying abnormal activation of Wnt/β-catenin signaling in prostate tumorigenesis. As 4100 AR co-regulators have been identified, 39 with their roles in prostate tumorigenesis remaining largely uncharacterized, this study provides a novel model that recapitulates the biological roles of AR and β-catenin, its co-regulator, during the course of PCa initiation and progression in vivo.
To determine the extent of the role that androgens have in prostate tumorigenesis, we pursued a series of castration experiments in this study. When mice were castrated at 2 weeks, prostate gland development was impaired in all mice with different genotypes and no PIN or other malignant lesions was observed in both Ctnnb1 (Figure 6a ). We observed significant regression of PIN and prostatic adenocarcinomas in both Ctnnb1 L(ex3)/+ /R26hAR L/+ :PB-Cre4 and Ctnnb1 L(ex3)/+ : PB-Cre4 mice. Importantly, when androgen pellets were implanted into castrated mice, we observed a re-growth of transgenic AR and stabilized β-catenin-positive prostate tumor cells (Supplementary Figure 5S) . Histological analyses of those prostate tissues showed more severe pathological changes in the prostate tissues isolated from Ctnnb1 L(ex3)/+ /R26hAR L/+ :PB-Cre4 than from Ctnnb1 L(ex3)/+ :PBCre4 mice. These data highlight the importance of androgen signaling in maintaining and promoting β-catenin-mediated prostatic tumor formation and progression and also correlate these mouse models with human early-onset PCa, which are thought to have a unique AR signature. 29 These features that mimic some unique aspects of early-onset PCa may also enable further study of these pathways potentially resulting in more target therapy development for PCa.
We observed either high-grade PIN or prostatic adenocarcinoma lesions in regenerated samples using epithelial cell suspensions isolated from Ctnnb1 L(ex3)/+ :PB-Cre4 or Ctnnb1 L(ex3)/+ / R26hAR L/+ :PB-Cre4 mice, respectively. Because prostatic cells with transgenic AR and stabilized β-catenin expression were also labeled with GFP expression, we confirmed that the regenerated PIN and adenocarcinoma lesions were derived solely from transgenic AR and stabilized β-catenin-expressing epithelial cells. In this set of experiments, regenerated PIN and cancerous lesions were very similar to the malignant changes that appeared in the prostates of Ctnnb1 L(ex3)/+ :PB-Cre4 or Ctnnb1 L(ex3)/+ /R26hAR L/+ : PB-Cre4 mice. The cell suspensions isolated from Ctnnb1 L(ex3)/+ / R26hAR L/+ :PB-Cre4 developed prostatic adenocarcinomas, whereas suspensions from Ctnnb1 L(ex3)/+ :PB-Cre4 mice only produced highgrade PIN lesions. This result further demonstrates a synergistic effect of co-expression of transgenic AR and stabilized β-catenin in promoting oncogenic transformation in prostate cells. In this study, we also directly implanted mouse PCa tissues in the grafting assays 40 and observed the similar results (Supplementary Figure S4) .
Using microarray approaches, we searched for the molecular targets that are responsible for PIN and prostatic adenocarcinoma development. We observed higher expression of several β-catenin downstream targets, including Lef1, Axin2 and Cd44, in the prostatic tissues of Ctnnb1 L(ex3)/+ :PB-Cre4 compared with those from Ctnnb1 L(ex3)/+ /R26hAR L/+ :PB-Cre4 and R26hAR L/+ :PB-Cre4 mice. We also observed a subset of pro-tumorigenic and pro-metastatic genes that show higher expression levels in prostate tissues of Ctnnb1 L(ex3)/+ /R26hAR L/+ :PB-Cre4 compound mice, including Spp1, Egr-1, Bex1, c-Myc and Sp6. SPP1 is a pro-metastasis invasion gene identified in human PCa that has been suggested as a prognostic marker for disease recurrence and lethal metastasis. 34 Increased Spp1 expression has been shown to contribute to the metastatic phenotype in both in vitro and in vivo studies. EGR-1 (early growth response-1) was upregulated in human prostate tumors and related to tumor progression. 35 Interestingly, Bex1 and Sp6 have also been implicated in breast cancer therapy resistance and linked to the regulation of Wnt-BMP signaling pathway. 41, 42 Because both AR and β-catenin are transcriptional regulators, we assessed their collaborative role in regulating transcription using our mouse models. We detected the recruitment of both AR and β-catenin on the endogenous mouse c-Myc promoter region. Intriguingly, the intensity of PCR fragments containing the β-catenin-binding regions was higher in the samples of 
/R26hAR
L/+ :PB-Cre4 mice. Currently, we are pursuing more mechanistic in-depth experiments to investigate the collaborative regulation of AR and β-catenin in distinct gene expression.
Finally, we observed that the most atypical and tumor cells in PIN and adenocarcinoma lesions of both Ctnnb1 L(ex3)/+ :PB-Cre4 and Ctnnb1 L(ex3)/+ /R26hAR L/+ :PB-Cre4 mice were E-cadherin and CK8 positive, but synaptophysin negative, suggesting that oncogenic transformation may be initiated in luminal epithelial cells. It has been shown that prostatic luminal epithelial cells are AR positive and can function as tumor-initiating cells, 43, 44 a feature of the tumor cells that we confirmed in our regeneration assays. Given the evidence that the probasin promoter is primarily active in prostatic luminal cells, our current data suggest that the dysregulation of androgen and β-catenin signaling pathways results in prostatic oncogenic transformation predominately in luminal epithelial cells. Furthermore, as demonstrated in this study, identification of a synergistic effect of AR and β-catenin on PCa development and progression suggests a novel mechanism for dysregulation of AR and β-catenin expression that is different from that of single gene, AR or β-catenin, alterations that potentially recapitulates features observed in early-onset PCa tumorigenesis. Therefore, more in-depth investigations using these newly developed mouse models should further enhance our knowledge regarding androgen and Wnt signaling pathways in prostate tumorigenesis. :PB-Cre4 littermates. Mice were genotyped by PCR as described previously. 31, 47, 48 The forward primer, 5′-TCCTCAGAGAGCCTCGGCTAGGTAG-3′, was used with the reverse primer, 5′-CCGTAAGTTATGTAACGCGGAACTC-3′ or 5′-TCTGTC TAGGGGTTGGATAAGCCAG-3′, to detect the AR target or wild-type allele, 31 respectively. The Ctnnb1 conditional and wild-type alleles were detected with the forward 5′-AACTGGCTTTTGGTGTCGGG-3′ and reverse primers 5′-TCGGTGGCTTGCTGATTATTTC-3′. 45 The forward primer 5′-TTGCCTGCA TTACCGGTCGATGCA-3′ and the reverse primer 5′-GATCCTGGCAATTTC GGCTAT-3′ were used to detect the Cre transgene. Genomic DNA fragments were amplified at 95°C for 3 min, 95°C for 45 s, 58°C for 40 s and 72°C for 60 s for 35 cycles and then at 72°C for 5 min.
MATERIALS AND METHODS
For castration, the mice were anesthetized by intraperitoneal injection of ketamine and xylazine. Both testicles and epididymis were removed through a scrotal approach. The distal end of the spermatic cord was ligated with silk thread as described previously. 49 For androgen treatment, testosterone pellets (12.5 mg, Innovative Research of America, Sarasota, FL, USA) were placed in castrated mice subcutaneously to restore serum testosterone level.
In vivo prostate regeneration assays , digested in Dulbecco's modified Eagle's medium/Collagenase/fetal bovine serum for 3 h at 37°C and 0.25% Trypsin-EDTA (Invitrogen, Carlsbad, CA, USA) on ice for 1 h. Digested cells were pipetted vigorously to dissociate cell clumps and then passed through 70-μm cell strainers (BD Biosciences, San Jose, CA, USA) to obtain single-cell suspensions. Mouse UGSM cells were prepared as described previously. 50 UGSM cells were cultured in Dulbecco's modified Eagle's medium/5% fetal bovine serum/5% Nuserum/5 μg/ml insulin/10 −8 M 5α-dihydrotestosterone. Approximately, 1 × 10 5 of prostatic epithelial and UGSM cells were mixed and resuspended in transplantation solution, 1:1 (v/v) phosphate-buffered saline:Matrigel (BD Biosciences) and transplanted under the renal capsule of 6-8-week-old male NOD/SCID mice.
Histological analyses and immunohistochemistry
In this study, we used the new guidelines recommended by The Mouse Models of Human Cancers Consortium Prostate Pathology Committee in 2013 for our pathological analyses. 32 Mouse tissues were fixed and processed as described in our previous study. 31 Tissue slides were exposed to different first antibodies in phosphate-buffered saline with 1% goat serum at 4°C overnight, including 1:500 dilution of anti-human AR (sc-7305, Santa Cruz, Dallas, TX, USA), 1:500 dilution of anti-mouse/human AR (sc-816, Santa Cruz), 1:250 dilution of anti-p63 (sc-8431, Santa Cruz), 1:3000 dilution of anti Ki67 (NCL-ki67, Novacastra, Buffalo Grove, IL, USA), 1:500 dilution of anti-β-catenin (sc-7199, Santa Cruz), 1:300 dilution of anti-Ecadherin (c20820, Transduction Laboratories, San Jose, CA, USA), 1:800 dilution of anti-CK5 (PRB-160P, Covance, San Diego, CA, USA), 1:800 dilution of anti-CK8 (MMS-162P, Covance), 1:200 dilution of antisynaptophysin (18-0130, Invitrogen), 1:100 dilution of anti-SPP1 (91655, Abcam, Cambridge, MA, USA) and 1:50 dilution of anti-Egr1 (4153, Cell Signaling, Danvers, MA, USA) antibodies. Slides were then incubated with biotinylated anti-rabbit or anti-mouse secondary antibody (BA-1000 or BA-9200, Vector Laboratories, Burlingame, CA, USA) for 1 h, horseradish peroxidase streptavidin (SA-5004, Vector Laboratories) for 30 min and then visualized by the DAB Kit (SK-4100, Vector Laboratories). All samples were subsequently counterstained with 5% (w/v) Harris Hematoxylin (Sigma-Aldrich Corp., St Louis, MO, USA).
